![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, January 18, 2013 2:12:15 PM
Dr. Menon and his teams took the pemetrexed discovery studies from Princeton to the human use form now called Alimta. How one can ignore that the raw active ingredient drug is not the same as the approved modified and buffered drug is beyond rational thinking.
Again, Dr. Menon has a Ph.D. in Pharmacology from Harvard. Period. Dr. Menon is a certified Toxicologist. Period. Dr. Menon is a Doctor of Veterinary Medicine. Period. Dr. Menon was the team leader for the animal studies that took the raw compound referred to as Pemetrexed through a process of discovery to the human drug Alimta. Period. He and his team invented Alimta from the base drug Pemetrexed.
Here are 3 free articles listed in PubMed. These 3 are out of a total 34 articles listed in PubMed with Teicher and Menon as authors; both of whom were team leaders. Please also note that the most recent article is 2009, meaning none of those team members would have worked with him if he lied about any qualifications or any aspects of projects he conducted with Teicher, including their joint role in the development of Alimta. Teicher and Menon published Alimta trials up to and including Phase 3 studies. Furthermore, Menon's publications are cited in dozens and dozens of studies using his work as foundational information. None of this would be the case if allegations of exaggeration or lying about credentials had any merit whatsoever.
Here are working links to 3 of the papers.
Preclinical studies in support of defibrotide for the treatment of multiple myeloma and other neoplasias.
Mitsiades CS, Rouleau C, Echart C, Menon K, Teicher B, Distaso M, Palumbo A, Boccadoro M, Anderson KC, Iacobelli M, Richardson PG.
Clin Cancer Res. 2009 Feb 15;15(4):1210-21.
Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human T98G glioblastoma multiforme xenografts.
Teicher BA, Menon K, Alvarez E, Galbreath E, Shih C, Faul M.
Clin Cancer Res. 2001 Mar;7(3):634-40.
Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts.
Teicher BA, Chen V, Shih C, Menon K, Forler PA, Phares VG, Amsrud T.
Clin Cancer Res. 2000 Mar;6(3):1016-23."
Here is a link to another 20 paper where Dr Menon is listed as a lead author also on the US Nation Library of Medicine National Institutes of Health
Alternatively, the scurrilous allegations seeking to discredit Dr Menon are from a discredited 'article' from a community news source which has since been removed due to it being entirely bogus. No link available as it was withdrawn.
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM